Search research articles
Contact Us
Filters
Showing results (261-270 of 383) with videos related to
Page
of 39
Sort By:
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
The Oncologist
|
September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
Breast Cancer Research and Treatment
|
March 13, 2024
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases
Qi Wu, Sigrid Hatse, Cindy Kenis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>-</sup>-Advanced Breast Cancer
Patrick Neven, Stephen R D Johnston, Masakazu Toi, et al.
Breast Cancer Research and Treatment
|
February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Caterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
Vanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
Breast (Edinburgh, Scotland)
|
December 3, 2024
Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer
Hava Izci, Gitte Zels, Anirudh Pabba, et al.
JAMA Network Open
|
August 26, 2024
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial
Heikki Joensuu, Judith Fraser, Hans Wildiers, et al.
Clinical Pharmacology and Therapeutics
|
June 25, 2020
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Anna Mueller-Schoell, Lena Klopp-Schulze, Werner Schroth, et al.
Page
of 39
Search research articles
Search
Showing results (261-270 of 383) with videos related to
Sort By:
Page
of 39
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
BMC Medicine
|
August 4, 2015
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
The Oncologist
|
September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
Breast Cancer Research and Treatment
|
March 13, 2024
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases
Qi Wu, Sigrid Hatse, Cindy Kenis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>-</sup>-Advanced Breast Cancer
Patrick Neven, Stephen R D Johnston, Masakazu Toi, et al.
Breast Cancer Research and Treatment
|
February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Caterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
Vanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
Breast (Edinburgh, Scotland)
|
December 3, 2024
Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer
Hava Izci, Gitte Zels, Anirudh Pabba, et al.
JAMA Network Open
|
August 26, 2024
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial
Heikki Joensuu, Judith Fraser, Hans Wildiers, et al.
Clinical Pharmacology and Therapeutics
|
June 25, 2020
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Anna Mueller-Schoell, Lena Klopp-Schulze, Werner Schroth, et al.
Page
of 39